FREMONT, Calif., Feb. 2, 2016 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused on gastrointestinal and renal diseases, today announced that Mike Raab, President and Chief Executive Officer, and David Rosenbaum, Ph.D., Senior Vice President of Drug Development, will participate in the 2016 Leerink Partners Global Healthcare Conference at 3:05 p.m. EST on Wednesday, February 10, 2016 at the Waldorf Astoria in New York City.
The analyst-led fireside chat will be available through a live audio webcast accessible through a link in the Investor Relations section of the Ardelyx website at ir.ardelyx.com. A replay of the webcast will be available for 30 days on the Company's website after the presentation.
Ardelyx is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative, minimally-systemic, small molecule therapeutics that work exclusively in the gastrointestinal tract to treat gastrointestinal and cardio-renal diseases. Ardelyx has developed a proprietary drug discovery and design platform enabling it, in a rapid and cost-efficient manner, to discover and design novel drug candidates. Utilizing this platform, Ardelyx has discovered and designed tenapanor, which it is evaluating for the treatment of constipation-predominant irritable bowel syndrome, or IBS-C, and management of hyperphosphatemia in patients with end stage renal disease. In addition to tenapanor, Ardelyx is developing RDX022, a non-absorbed polymer for the treatment of hyperkalemia, or high potassium, in kidney and heart disease patients. Ardelyx is also advancing several research programs focused in gastrointestinal and cardio-renal diseases. Ardelyx is located in Fremont, California.